Psychiatric Times

05/02/2026

ICYMI: Auvelity for the treatment of Alzheimer disease dementia is now FDA approved. Read the news here ⬇️

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

05/01/2026

Learn about unmet needs in effectively treating patients with MDD, and explore the latest research in digital therapeutics for depression symptoms. Watch now: bit.ly/48wGdkX

05/01/2026

New survey data from the Schizophrenia Policy Action Network show that despite growing recognition of serious mental illness as a treatable medical condition, access to consistent, evidence-based care remains limited.

The SPAN survey underscores gaps in schizophrenia care access as new treatments emerge, citing coverage and continuity challenges.

05/01/2026

Our May theme: Psychedelics.

We want to hear your clinical insights! Submit to our content series ⬇️
https://www.psychiatrictimes.com/view/presenting-our-may-2026-theme-psychedelics

05/01/2026

Approximately 50% to 70% of individuals with ADHD have comorbid sleep disturbances.

Amit Chopra will share further insights in his upcoming presentation with The American Society for Adolescent Psychiatry.

Sleep disorders commonly occur in young patients with ADHD. See how to monitor and treat these issues.

04/30/2026

🚨 BREAKING NEWS: The FDA has approved Axsome Therapeutics'
oral dextromethorphan-bupropion (Auvelity, formerly known as AXS-05) for the treatment of agitation associated with Alzheimer disease.

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

04/30/2026

Videra Health’s video-based AI screening tool, TDScreen, was able to identify symptoms of tardive dyskinesia and prompt patients to seek clinical evaluation. Of patients who received a diagnosis from the screening tool, 80% continued on to receive treatment by a clinician.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

04/29/2026

Spot delirium in the ICU early with MD‑MOSAIC: an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes.

Spot ICU delirium early with MD‑MOSAIC—an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes.

04/28/2026

Narcolepsy is more than excessive sleepiness. It is a disorder of sleep-wake instability that can be difficult to recognize in psychiatric populations. In this Peer Exchange, Dr. Karl Doghramji, MD, Dr. Michael Strunc, MD, Ellen Wermter, FNP-BC, and Dr. Christopher Winter, MD break down how to recognize and diagnose narcolepsy, navigate treatment selection and DEA scheduling considerations, and deliver multidisciplinary, long-term care across all age groups.

Watch here: https://hubs.li/Q04dMGxX0

04/27/2026

An application for Adial Pharmaceuticals' AD04 has been submitted to the FDA's Commissioner’s National Priority Voucher Pilot Program, which could lead to expedited FDA review.

AD04 is currently being developed for the treatment of patients with alcohol use disorder and a specific biomarker.

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

04/27/2026

The FDA has approved the sNDA based on long-term data evaluating the safety and efficacy of Johnson & Johnson's Caplyta for the prevention of relapse in schizophrenia.

Caplyta demonstrated a 63% lower risk of relapse compared with placebo.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.

04/25/2026

Need something to read this weekend? The entire April issue is now live on our website. Read it here: https://www.psychiatrictimes.com/journals/psychiatric-times/volume-43-issue-4